COVID-19 (SARS-CoV-2)
Coronavirus disease 2019 (COVID-19) was first identified in December 2019, and it has since spread globally, resulting in the ongoing pandemic. The majority of the cases result in mild symptoms, however some progress to pneumonia and multi-organ failure. The overall mortality rate for this disease was up to 4.6% (ranging from 0.2% to 15% according to age group and other health problems). SARS-CoV-2 is predominantly transmitted by droplet infection via coughing or sneezing and through close contact with infected persons. The incubation time of SARS-CoV-2 is three to seven days, maximally 14 days. It is suspected that the total number of reported COVID-19 infectious is underestimated, as there are many mild or asymptomatic cases that go undetected.
|
Product Summary |
Antibody |
Antibody Against |
Regulatory Approval |
|
|
Nucleocapsid |
Spike |
|||
|
COVID19N-REAADTM Anti-SARS-CoV-2 Nucleocapsid Protein IgG ELISA |
IgG |
✔ |
HSA's Provisional Authorisation (PA) & |
|
|
COVID19-REAADTM Anti-SARS-CoV-2 IgG |
IgG |
✔ |
✔ |
HSA's Provisional Authorisation (PA), Malaysian |
|
COVID19-REAAD™ Anti-SARS-CoV-2 Total Antibodies |
Total Antibodies |
✔ |
✔ |
European CE |
|
COVID19S-REAAD™ Anti-SARS-CoV-2 Spike Protein |
Total Antibodies |
✔ |
European CE |
|
About COVID19N-REAAD™
Anti-SARS-CoV-2 Nucleocapsid Protein IgG ELISA
COVID19N-REAAD™ Anti-SARS-CoV-2 Nucleocapsid Protein IgG ELISA is an enzyme-linked immunosorbent assay intended for qualitative detection of IgG antibodies to SARS-CoV-2 Nucleocapsid Protein in human serum and plasma (EDTA). COVID19-REAAD™ is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. COVID19-REAAD™ should not be used as the sole basis for diagnosis.
This product had received Provisional Authorisation (PA) & Pandemic Special Access Route (PSAR) from Singapore’s Health Sciences Authority (HSA), and European CE for professional use.
About COVID19-REAAD™
Anti-SARS-CoV-2 IgG ELISA
COVID19-REAAD™ Anti-SARS-CoV-2 IgG ELISA is an enzyme-linked immunosorbent assay intended for qualitative and quantitative detection of SARS-CoV-2 IgG antibodies in human serum and plasma. COVID19-REAAD™ Anti-SARS-CoV-2 IgG ELISA has been calibrated against the “First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human)”, NIBSC code: 20/136. COVID19-REAAD™ is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. COVID19-REAAD™ should not be used as the sole basis for diagnosis.
This product had received Provisional Authorisation (PA) from Singapore’s Health Sciences Authority (HSA), Malaysian Emergency Use Authorisation (EUA), and European CE for professional use.
About COVID19-REAAD™
Anti-SARS-CoV-2 Total Antibodies ELISA
COVID19-REAAD™ Anti-SARS-CoV-2 Total Antibodies ELISA is an enzyme-linked immunosorbent assay intended for qualitative and quantitative detection of total antibodies to SARS-CoV-2 Nucleocapsid & Spike Proteins in human serum and plasma. COVID19-REAAD™ is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. COVID19-REAAD™ should not be used as the sole basis for diagnosis.
This product had received approval for professional use from European CE.
About COVID19S-REAAD™
Anti-SARS-CoV-2 Spike Protein Total Antibodies ELISA
COVID19S-REAAD™ Anti-SARS-CoV-2 Spike Protein Total Antibodies ELISA is an enzyme-linked immunosorbent assay intended for qualitative and quantitative detection of total antibodies to SARS-CoV-2 Spike Protein in human serum and plasma. COVID19S-REAAD™ Anti-SARS-CoV-2 Spike Protein Total Antibodies ELISA has been calibrated against the “First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human)”, NIBSC code: 20/136. COVID19S-REAAD™ is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. COVID19-REAAD™ should not be used as the sole basis for diagnosis.
This product had received approval for professional use from European CE.